Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label dose-escalation study of EDI200 in male neonates with XLHED
2012-003561-17Phase 2Completed
- Sponsor
- Edimer Pharmaceuticals
- Start
- Mar 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EDI200 in ectodermal dysplasia 15 (HED) and Anhidrotic ectodermal dysplasia (HED), sponsored by Edimer Pharmaceuticals. Started Mar 2013; status: completed.
02
Drugs
EDI200
03
Conditions
ectodermal dysplasia 15 (HED)Anhidrotic ectodermal dysplasia (HED)
Beyond the preview
Go deeper on 2012-003561-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003561-17.